Thao Truong
Family Medicine · Magnolia, TXNPI 1740202910
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $534 and has fallen 56.3% since, to $234 in 2025.
Across 111 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$322
- AstraZeneca$271
- Amgen$249
- Novo Nordisk$217
- Pfizer$201
- Teva Pharmaceuticals USA, Inc.$141
- plus $832 from 13 others
What the payments were for
- Food & beverage$2,20399%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $322 |
| AstraZeneca | 14 | $271 |
| Amgen | 16 | $249 |
| Novo Nordisk | 12 | $217 |
| Pfizer | 10 | $201 |
| Teva Pharmaceuticals USA, Inc. | 2 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $127 |
| Lilly USA, LLC | 7 | $108 |
| Boehringer Ingelheim | 4 | $105 |
| Johnson & Johnson | 3 | $87 |
| Corium, LLC | 4 | $79 |
| GSK | 4 | $78 |
| Merck | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Abbott | 2 | $48 |
| Pulmonx Corporation | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,232 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $81,073 |
| JardianceEmpagliflozin | 38 | $56,216 |
| TrulicityDulaglutide | 39 | $54,729 |
| EliquisApixaban | 25 | $37,118 |
| XareltoRivaroxaban | 17 | $23,974 |
| FarxigaDapagliflozin Propanediol | 16 | $21,422 |
| JanuviaSitagliptin Phosphate | 11 | $19,239 |
| MounjaroTirzepatide | 15 | $16,464 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| Bydureon BciseExenatide Microspheres | 15 | $11,793 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $7,183 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,358 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $2,766 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,435 |
| Famotidine | 75 | $2,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $217 | $81,07362 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $108 | $71,19354 claims |
| Boehringer IngelheimJardiance | $105 | $56,21638 claims |
| PfizerEliquis | $201 | $37,11825 claims |
| AstraZenecaFarxiga, Symbicort | $271 | $28,60540 claims |
| Johnson & JohnsonXarelto | $87 | $23,97417 claims |
| MerckJanuvia | $77 | $19,23911 claims |
| AbbVieVraylar | $322 | $16,00011 claims |
| GSKIncruse Ellipta | $78 | $4,35812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Magnolia
- Feras ElhajjMagnolia$37K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.